Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) (Ascending) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
62756-0131-01 62756-0131 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 In Use
62756-0131-02 62756-0131 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 In Use
62756-0181-01 62756-0181 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 Dec. 31, 2006 No Longer Used
62756-0182-01 62756-0182 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 Dec. 31, 2006 No Longer Used
62756-0219-60 62756-0219 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 In Use
62756-0238-18 62756-0238 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0238-86 62756-0238 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0238-88 62756-0238 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0239-18 62756-0239 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0239-20 62756-0239 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use

Found 10,000 results in 8 milliseconds — Export these results